Johnson & Johnson EBIT 2010-2024 | JNJ
Johnson & Johnson annual and quarterly EBIT history from 2010 to 2024. EBIT can be defined as earnings before interest and taxes.
- Johnson & Johnson EBIT for the quarter ending June 30, 2024 was $6.413B, a 6.37% decline year-over-year.
- Johnson & Johnson EBIT for the twelve months ending June 30, 2024 was $21.769B, a 52.65% increase year-over-year.
- Johnson & Johnson 2023 annual EBIT was $17.095B, a 15.06% decline from 2022.
- Johnson & Johnson 2022 annual EBIT was $20.125B, a 3.66% increase from 2021.
- Johnson & Johnson 2021 annual EBIT was $19.414B, a 15.5% increase from 2020.
Johnson & Johnson Annual EBIT
(Millions of US $) |
| 2023 |
$17,095 |
| 2022 |
$20,125 |
| 2021 |
$19,414 |
| 2020 |
$16,809 |
| 2019 |
$18,003 |
| 2018 |
$19,615 |
| 2017 |
$18,992 |
| 2016 |
$20,897 |
| 2015 |
$19,876 |
| 2014 |
$21,163 |
| 2013 |
$16,027 |
| 2012 |
$14,371 |
| 2011 |
$13,023 |
| 2010 |
$17,509 |
| 2009 |
$16,296 |
Johnson & Johnson Quarterly EBIT
(Millions of US $) |
| 2024-06-30 |
$6,413 |
| 2024-03-31 |
$4,233 |
| 2023-12-31 |
$5,340 |
| 2023-09-30 |
$5,783 |
| 2023-06-30 |
$6,849 |
| 2023-03-31 |
$-877 |
| 2022-12-31 |
$2,916 |
| 2022-09-30 |
$5,373 |
| 2022-06-30 |
$5,942 |
| 2022-03-31 |
$5,894 |
| 2021-12-31 |
$1,311 |
| 2021-09-30 |
$3,882 |
| 2021-06-30 |
$6,714 |
| 2021-03-31 |
$7,507 |
| 2020-12-31 |
$1,747 |
| 2020-09-30 |
$4,457 |
| 2020-06-30 |
$4,004 |
| 2020-03-31 |
$6,601 |
| 2019-12-31 |
$4,384 |
| 2019-09-30 |
$1,784 |
| 2019-06-30 |
$7,212 |
| 2019-03-31 |
$4,623 |
| 2018-12-31 |
$3,568 |
| 2018-09-30 |
$4,841 |
| 2018-06-30 |
$5,352 |
| 2018-03-31 |
$5,854 |
| 2017-12-31 |
$2,919 |
| 2017-09-30 |
$5,093 |
| 2017-06-30 |
$5,080 |
| 2017-03-31 |
$5,900 |
| 2016-12-31 |
$4,608 |
| 2016-09-30 |
$5,570 |
| 2016-06-30 |
$5,182 |
| 2016-03-31 |
$5,537 |
| 2015-12-31 |
$3,971 |
| 2015-09-30 |
$4,277 |
| 2015-06-30 |
$5,896 |
| 2015-03-31 |
$5,732 |
| 2014-12-31 |
$2,859 |
| 2014-09-30 |
$6,958 |
| 2014-06-30 |
$5,768 |
| 2014-03-31 |
$5,578 |
| 2013-12-31 |
$2,902 |
| 2013-09-30 |
$3,790 |
| 2013-06-30 |
$4,928 |
| 2013-03-31 |
$4,407 |
| 2012-12-31 |
$3,225 |
| 2012-09-30 |
$3,745 |
| 2012-06-30 |
$2,192 |
| 2012-03-31 |
$5,209 |
| 2011-12-31 |
$536 |
| 2011-09-30 |
$4,262 |
| 2011-06-30 |
$3,569 |
| 2011-03-31 |
$4,656 |
| 2010-12-31 |
$2,390 |
| 2010-09-30 |
$4,340 |
| 2010-06-30 |
$4,364 |
| 2010-03-31 |
$6,415 |
| 2009-12-31 |
$2,709 |
| 2009-09-30 |
$4,415 |
| 2009-06-30 |
$4,398 |
| 2009-03-31 |
$4,774 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$399.964B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
